R. Petrioli, E. Francini, F. Roviello
Mar 6, 2015
Citations
0
Influential Citations
26
Citations
Quality indicators
Journal
Cancer Chemotherapy and Pharmacology
Abstract
AbstractPurpose The aim of this study was to evaluate the activity and safety of epirubicin (EPI), oxaliplatin (l-OHP) and 5fluorouracil (5FU) (EOF) followed by docetaxel (D), l-OHP and 5FU (DOF) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer.MethodsForty-five patients were enrolled: 26 gastric and 19 GEJ cancer. Median age was 69 years (range 34–83); ECOG performance status was 0–1 in 37 patients. Treatment consisted of EPI 50 mg/m2 combined with l-OHP 130 mg/m2 on day 1 and continuous infusion 5FU 750 mg/m2 days 1–5 (EOF), every 3 weeks for a maximum of 4 cycles. After EOF completion, patients received D 70 mg/m2 combined with l-OHP 130 mg/m2 on day 1 and continuous infusion 5FU 750 mg/m2 days 1–5 (DOF), every 3 weeks for a maximum of 4 cycles.ResultsAfter sequential EOF/DOF, the overall response rate was 51.1 % (95 % CI 35.7–66.2 %) and 93.3 % of patients were progression free 6 months after the onset of chemotherapy. The median progression-free survival was 9.5 months (95 % CI 8.0–11.9 months), and the median overall survival was 15.8 months (95 % CI 13.6–18.9 months). Grade 3 neutropenia was observed in 15 patients (33.3 %) after sequential EOF/DOF.ConclusionsThe sequential treatment EOF/DOF is feasible in well-selected patients with advanced gastric or GEJ cancer and shows encouraging survival results.